DeCure for Maturity-onset diabetes of the young type 6
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for maturity-onset diabetes of the young type 6 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMaturity-onset diabetes of the young type 6 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for maturity-onset diabetes of the young type 6 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glucokinase (GCK) — GCK is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4DCH · 1.79 Å · ligand (2R)-3-cyclopentyl-2-[4-(methylsulfonyl)phenyl]-N-(1,3-thiazol-2-yl)propanamide (4DC). Experimental structure, not a prediction.
What the evidence adds up to
A 2021 hypothesis argues that recessive MODY variants probably exist but have been missed because they produce no family history of monogenic diabetes. The paper notes that all currently recognised MODY forms are dominantly inherited and asks whether pancreatic beta cells are only harmed by heterozygous variants. No data, no patient numbers, no clinical outcomes are given; it is a theoretical proposal.
A 2025 report announces a new MODY subtype from India, MODY 15, but the text provided contains no genetic, biochemical or clinical details about this subtype. It only recounts that diabetes classification once used age cut-offs—under 40 years was called "growth onset diabetes", over 40 years "maturity onset diabetes"—and that those labels were later equated to type 1 and type 2 diabetes. No patient data, no diagnostic criteria, no outcomes are presented.
A 2024 case report asks whether standard continuous glucose monitoring (CGM) data can identify a characteristic "glucotype" in HNF1B MODY-5. The abstract states that MODY-5 is infrequent, caused by HNF1B mutations, and produces high glycemic variability similar to type 1 diabetes once residual insulin secretion declines, plus renal, gynecologic and pancreatic developmental abnormalities. The report describes a single clinical case but gives no numerical results, no comparison group, and no conclusion about whether CGM can reliably identify the glucotype.
What is missing: large-scale genetic screening to test the recessive MODY hypothesis, full characterisation of the MODY 15 subtype including causal gene and penetrance data, and a prospective study with enough patients to validate CGM-based glucotyping for MODY-5. No trial funding, no stratified cohort, and no replication of the single case are reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Trends in Genetics · 2021 · 3 citations · open access
Why all MODY variants are dominantly inherited: a hypothesis
AbstractMaturity-onset diabetes in the young (MODY) comprises monogenic phenotypes of young-onset, insulinopenic diabetes. All its forms are dominantly inherited. Why? Are the pancreatic β cells only harmed by heterozygous variants? We propose that recessive MODYs do exist but have escaped detection due to lack of family history suggestive of monogenic inheritance.
Journal of the Association of Physicians of India · 2025 · 1 citations
Exciting Discovery of a New Maturity-onset Diabetes of the Young Subtype from India (MODY 15)
AbstractAt that time, the classification of diabetes was based purely on the age at onset of diabetes. Those diagnosed with diabetes below 40 years of age were labeled as "growth onset diabetes," while those with onset at or above the age of 40 years were referred to as "maturity onset diabetes." At that time, these types were believed to be equivalent to what are known as type 1 diabetes (T1D) and type 2 diabetes (T2D) today.
Annales d Endocrinologie · 2024 · 0 citations · open access
Can standard CGM data be used to identify an HNF1B MODY-5 glucotype? Insights from a clinical case
AbstractIntroduction : Diagnosing and managing maturity-onset diabetes of the young (MODY) is clinically challenging. Hepatocyte nuclear factor-1β (HNF1B) diabetes (MODY-5) is infrequent MODY subtype, characterized by mutations leading to a clustered phenotype with high glycemic variability, as seen in type 1 diabetes once residual insulin secretion wanes, and to renal, gynecologic and pancreatic developmental abnormalities. [...]
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
